Augmedix Delivers 40% Revenue Growth for First Quarter of 2024
Augmedix (Nasdaq: AUGX) reported a 40% revenue growth for Q1 2024, with revenues reaching $13.5 million compared to $9.6 million in Q1 2023. Gross profit increased by 45% to $6.3 million, and gross margin improved by 150 basis points to 47.1%. Net revenue retention was 143%, and the company expects continued growth throughout 2024. However, there has been a slow-down in purchasing commitments as providers evaluate various AI offerings. Net loss increased by 24% to $6.5 million, and operating expenses rose by 32% to $12.7 million. Augmedix adjusted its full-year revenue outlook to $52-$55 million. The company is seeing strong interest in its AI products, Augmedix Go and Augmedix Go Assist, particularly in emergency care settings.
- 40% revenue growth, reaching $13.5 million in Q1 2024.
- Gross profit increased by 45% to $6.3 million.
- Gross margin improved by 150 basis points to 47.1%.
- Net revenue retention rate of 143%.
- Strong interest in AI products, particularly Augmedix Go and Go Assist.
- Cash and cash equivalents increased to $37.3 million from $19.9 million in Q1 2023.
- HCA Healthcare plans to expand Augmedix Go to additional emergency departments.
- Net loss increased by 24% to $6.5 million.
- Operating expenses rose by 32% to $12.7 million.
- Operating cash burn increased to $8.2 million from $6.2 million.
- Some providers are slowing down purchasing commitments.
- Transition to AI-based solutions may result in slower short-term revenue growth.
- Adjusted EBITDA loss increased to $5.1 million from $4.3 million.
Insights
The 40% revenue growth is a significant indicator of Augmedix's current market performance, suggesting strong demand for its AI-based medical documentation solutions. However, it's essential to note the company’s net loss widened to
The company's revised revenue guidance of
The substantial cash reserves of
The healthcare market's adoption of AI-based solutions is a significant trend and Augmedix is well-positioned within this space. The introduction of the ER version of Augmedix Go is particularly noteworthy, as it taps into the acute care segment, which is a critical area with substantial documentation needs. The traction with major players like HCA Healthcare validates the product’s efficacy and market fit. However, the slower purchasing commitments reflect a cautious approach by health systems, likely due to the nascent stage of AI integration in medical documentation.
The transition from the traditional Augmedix Live to AI-based products like Augmedix Go and Go Assist suggests a strategic pivot towards higher-margin products. This shift, although resulting in short-term revenue dips due to lower ARPU, presents potential for long-term growth as these AI solutions could capture a larger market share with their cost-efficiency and advanced capabilities. The high net revenue retention of
The development and deployment of fully-automated, generative-AI powered products like Augmedix Go is a significant technological advancement in medical documentation. Generative AI has the potential to drastically reduce the time clinicians spend on documentation, thereby increasing efficiency and reducing burnout. This efficiency gain is important in high-stress environments like emergency rooms, where the ER version's early success highlights a substantial market need.
One challenge that stands out is the slow adoption curve of these advanced AI solutions, as health systems are cautiously evaluating multiple offerings. This is common in fields with high regulatory scrutiny and critical operational impacts. The slower near-term revenue growth due to transitions from established products to AI solutions might appear as a drawback, but it aligns with the broader industry trend of transitioning towards more scalable and economically viable AI-driven solutions. Augmedix’s approach of providing a comprehensive product portfolio ensures they cater to varying levels of technological readiness across healthcare providers.
SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024.
“Augmedix delivered in-line first quarter performance, with
“We are seeing an increasing amount of interest with new and existing customers that are evaluating our AI products, Augmedix Go and Augmedix Go Assist, including active discussions for large deployments. In particular, the recently introduced ER version is resonating with health systems as it is the first fully-automated, generative AI powered medical documentation product for acute care. Augmedix Go Assist is quickly becoming a compelling solution given its attractive mix of price and efficiency. Meanwhile, following a successful pilot, our strategic partner HCA Healthcare is planning to expand Augmedix Go to additional emergency departments within its health system."
“At the same time, we have observed a slow-down in purchasing commitments by some providers as they evaluate the many AI offerings currently available. Based on current expectations, we now believe it is prudent to adjust our full year revenue outlook to reflect these developments that have arisen since the last earnings call,” continued Krakaris. “We are continuing to sell cohorts of new Live users, although not at the level that we had previously expected, while providers evaluate various AI offerings, including our own. A couple of our health systems have chosen to transition some of their Augmedix Live users to Augmedix Go Assist, reducing the near-term revenue expectations at these accounts. While the transition from our established Live product to our AI-based solutions, Augmedix Go and Augmedix Go Assist, may result in slower short-term revenue growth given the lower APRU of our AI products, we welcome this transition as it exposes us to a much larger segment of the market. We expect this will ultimately result in robust revenue growth going forward that is generated from products with inherently higher gross margins than our established Live product.”
Concluded Krakaris, “Our strategic positioning has always been to meet customers where they are today and where they want to be in the future. For this reason, we offer health systems the most comprehensive portfolio of products in the industry, giving unrivaled flexibility and value to users, that allow customers to select the optimal solution based on the clinician and the encounter. The market is trying to balance the need for medical note accuracy and completeness against cost-effective optimization. We believe offering solutions that span this spectrum is the winning approach at this juncture of AI’s evolution. This is being validated, in fact, by the strong early interest in our AI-based products. Augmedix is ideally positioned, with the right blend of solutions, strong AI capabilities, and a pipeline of forward-thinking healthcare systems and clinicians who are helping us optimize our suite of solutions.”
| Three Months Ended March 31, | ||||||||||
| Financial Highlights: | 2024 | 2023 | Change | |||||||
| Revenues | ||||||||||
| Gross profit | ||||||||||
| Gross margin | 150 bps | |||||||||
| Net loss | (24)% | |||||||||
| Loss per share | ||||||||||
| Adjusted EBITDA (non-GAAP) | (19)% | |||||||||
First Quarter 2024 Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended March 31, 2023.
- Total revenue was
$13.5 million , an increase of40% compared to$9.6 million . - Dollar-based Net Revenue Retention was
143% for our Health Enterprise customers compared to136% . - Gross Profit increased
45% to$6.3 million from$4.4 million . - Gross Margin increased 150 basis points to
47.1% compared to45.6% . - Operating Expenses were
$12.7 million compared to$9.5 million . Adjusted operating expenses, a Non-GAAP metric, increased32% to$11.9 million compared to$9.0 million . - Net loss was
$6.5 million compared to$5.2 million . - Adjusted EBITDA loss, a Non-GAAP metric, was
$5.1 million compared to$4.3 million . - Operating cash burn was
$8.2 million compared to$6.2 million . - Cash and cash equivalents, as of March 31, 2024, was
$37.3 million compared to$19.9 million as of March 31, 2023. - Common shares and pre-funded warrants outstanding as of March 31, 2024 were 53,146,326. The pre-funded warrants are included in the weighted average shares outstanding for the EPS calculation. Net exercising
100% of the remaining warrants and100% of the fully-vested and in-the-money employee equity awards at a price of$2.22 per share would add another approximately 2.3 million common shares.
Adjusted operating expenses and Adjusted EBITDA are Non-GAAP financial measures. See “Non-GAAP Financial Measures.” Please see “Non-GAAP Financial Measures” below and the Reconciliation of GAAP to Non-GAAP Metrics table below.
2024 Revenue Guidance
Based on our current outlook, Augmedix expects to generate revenue of approximately
Conference Call
Augmedix will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT today, Monday, May 13, 2024, to discuss its first quarter 2024 financial results. The conference call can be accessed by dialing + 1-877-407-3982 for U.S. participants or +1 (201) 493-6780 for international participants and referencing conference ID # 13746028. Interested parties may access a live and archived webcast on the “Investor Relations” section of the Company’s website at: ir.augmedix.com.
Definition of Key Metrics
Average Clinicians in Service: We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using our products. We average the month-end number of clinicians in service for all months in the measurement period and the number of clinicians in service at the end of the month immediately preceding the measurement period. We believe growth in the average number of clinicians in service is a key indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business. At this time clinicians in service does not include clinicians using Augmedix Go.
Average Annual Revenue Per Clinician: Average revenue per clinician is determined as total revenue, excluding Data Services revenue, recognized during the period presented divided by the average number of clinicians in service during that same period. Using the number of clinicians in service at the end of each month, we derive an average number of clinicians in service for the periods presented. The average annual revenue per clinician will vary based upon minimum hours of service requested by clinicians, pricing, and our product mix.
Dollar-Based Net Revenue Retention: Dollar-based net revenue retention is determined as the revenue from Health Enterprises as of twelve months prior to such period end as compared to revenue from these same Health Enterprises as of the current period end, or current period revenue. We define a "Health Enterprise" as a company or network of doctors that has at least 50 clinicians currently employed or affiliated that could utilize our services. Current period revenue includes any expansion or new products and is net of contraction or churn over the trailing twelve months but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based net revenue retention is a key indicator of the performance of our business as it demonstrates our ability to increase revenue across our existing customer base through expansion of users and products, as well as our ability to retain existing customers.
About Augmedix
Augmedix (Nasdaq: AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.
The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decision support.
Incorporating data from millions of interactions across all care settings, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes.
Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.
Non-GAAP Financial Measures
To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: adjusted operating expenses, and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
We define Adjusted Operating Expense as total operating expenses less share-based compensation expense.
In the fourth quarter of 2023, Augmedix changed its computation of Adjusted EBITDA to better reflect the performance of the Company’s business predominantly due to the equity financing that occurred in November of 2023, which significantly increased the Company’s cash balance. We now define Adjusted EBITDA as net income (loss) adjusted to exclude depreciation and amortization; share-based compensation expense; income tax expense (benefit); and other income (expense) net, which consists of interest expense on our debt facility, interest income from our cash and cash equivalents, realized foreign currency gains and losses, loss on extinguishment of debt, change in fair value of a warrant liability, and grant income from the Bangladesh government related to our Bangladesh subsidiary. Prior to the fourth quarter of 2023, the Company did not exclude interest income earned on cash balances, realized foreign currency transaction gains or losses or grant income received from the Bangladesh government from the computation of Adjusted EBITDA. Adjusted EBITDA has been recast in prior periods to reflect this change for consistency in presentation.
We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results. We believe that both management and investors benefit from reviewing these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and liquidity as well as comparisons to our competitors' operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.
There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.
For more information on the non-GAAP financial measures, please see the Reconciliation of GAAP to non-GAAP Metrics table in this press release. This accompanying table includes details on the GAAP financial measures that are most directly comparable to Non-GAAP financial measures and the related reconciliations between these financial measures.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve a number of risks and uncertainties. Words such as "believes," "may," "will," "estimates," "potential," "continues," "anticipates," "intends," "expects," "could," "would," "projects," "plans," "targets," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding full-year revenue guidance for 2024; our confidence about our positioning within the medical documentation market, and our expectation to report continued growth throughout the rest of the year; Go Assist quickly becoming a compelling solution; HCA Healthcare’s plans to expand Augmedix Go to additional emergency departments within its health system; our observation of a slow-down in purchasing commitments by some providers; the transition by customers from our Live product to our AI-based solutions exposing us to a much larger segment of the market that will ultimately result in robust revenue growth going forward that is generated from products with inherently higher gross margins than our Live product; our offering to health systems the most comprehensive portfolio of products in the industry, giving unrivaled flexibility and value to users; the market trying to balance the need for medical note accuracy and completeness against cost-effective optimization and our belief that our offering solutions that span this spectrum are the winning approach at this juncture of AI’s evolution; the strong early interest in our AI-based products; and Augmedix being ideally positioned, with the right blend of solutions, strong AI capabilities, and a pipeline of forward-thinking healthcare systems and clinicians who are helping us optimize our suite of solutions. Forward-looking statements are based on management's expectations as of the date of this filing and are subject to a number of risks, uncertainties and assumptions, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the Securities and Exchange Commission on March 26, 2024 as well as other documents that may be filed by us from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward looking statements: our expectations regarding changes in regulatory requirements; our ability to interoperate with the electronic health record systems of our customers; our reliance on vendors; our ability to attract and retain key personnel; anticipated trends, growth rates, and challenges in our business and in the markets in which we operate; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; developments and projections relating to our competitors and our industry, including competing dictation software providers, third-party, non-real time medical note generators and real time medical note documentation services, as well as our ability to compete effectively in the market; and the impact of current and future laws and regulations. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investors:
Matt Chesler, CFA
FNK IR
investors@augmedix.com
Media:
Kaila Grafeman
Augmedix
pr@augmedix.com
| AUGMEDIX, INC. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except shares and key metrics) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenues | $ | 13,471 | $ | 9,628 | ||||
| Cost of revenues | 7,130 | 5,242 | ||||||
| Gross profit | 6,341 | 4,386 | ||||||
| Operating expenses: | ||||||||
| General and administrative | 5,347 | 4,207 | ||||||
| Sales and marketing | 3,563 | 2,563 | ||||||
| Research and development | 3,833 | 2,710 | ||||||
| Total operating expenses | 12,743 | 9,480 | ||||||
| Loss from operations | (6,402 | ) | (5,094 | ) | ||||
| Other income (expenses): | ||||||||
| Interest expense | (616 | ) | (408 | ) | ||||
| Interest income | 503 | 162 | ||||||
| Other | (64 | ) | 134 | |||||
| Total other income (expenses), net | (177 | ) | (112 | ) | ||||
| Net loss before income taxes | (6,579 | ) | (5,206 | ) | ||||
| Income tax expense (benefit) | (80 | ) | 33 | |||||
| Net loss | $ | (6,499 | ) | $ | (5,239 | ) | ||
| Weighted average shares of common stock outstanding, basic and diluted | 53,058,667 | 37,491,072 | ||||||
| Key Metrics: | ||||||||
| Average clinicians in service | 1,862 | 1,371 | ||||||
| Average annual revenue per clinician | $ | 28,700 | $ | 27,800 | ||||
| Dollar-based net revenue retention rate | 143 | % | 136 | % | ||||
| AUGMEDIX, INC. Condensed Consolidated Balance Sheet (Unaudited, in thousands) | ||||||||
| March 31, 2024 | December 31, 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 37,301 | $ | 46,217 | ||||
| Restricted cash | 125 | 125 | ||||||
| Accounts receivable, net of allowance for credit losses of | 9,979 | 8,572 | ||||||
| Prepaid expenses and other current assets | 2,568 | 1,909 | ||||||
| Total current assets | 49,973 | 56,823 | ||||||
| Property and equipment, net | 3,597 | 3,739 | ||||||
| Operating lease right of use asset | 4,918 | 5,220 | ||||||
| Restricted cash, non-current | 209 | — | ||||||
| Deposits and other assets | 859 | 930 | ||||||
| Total assets | $ | 59,556 | $ | 66,712 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,245 | $ | 721 | ||||
| Accrued expenses and other current liabilities | 4,429 | 6,589 | ||||||
| Deferred revenue | 9,014 | 8,963 | ||||||
| Customer deposits | 851 | 851 | ||||||
| Operating lease liability, current portion | 1,487 | 1,494 | ||||||
| Loan payable, current portion | 7,500 | 5,000 | ||||||
| Total current liabilities | 24,526 | 23,618 | ||||||
| Operating lease liability, net of current portion | 3,751 | 4,049 | ||||||
| Loan payable, net of current portion | 12,952 | 15,303 | ||||||
| Other liabilities | 548 | 421 | ||||||
| Total liabilities | 41,777 | 43,391 | ||||||
| Total stockholders' equity | 17,779 | 23,321 | ||||||
| Total liabilities and stockholders' equity | $ | 59,556 | $ | 66,712 | ||||
| AUGMEDIX, INC. Condensed Consolidated Statement of Cash Flows (Unaudited, in thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Net cash used in operating activities | $ | (8,236 | ) | $ | (6,221 | ) | ||
| Net cash used in investing activities | (542 | ) | (173 | ) | ||||
| Net cash provided by financing activities | 59 | 5,085 | ||||||
| Effect of exchange rate changes on cash and restricted cash | 12 | (40 | ) | |||||
| Net decrease in cash and restricted cash | (8,707 | ) | (1,349 | ) | ||||
| Cash and restricted cash at beginning of year | 46,342 | 21,988 | ||||||
| Cash and restricted cash at end of year | $ | 37,635 | $ | 20,639 | ||||
| AUGMEDIX, INC. Reconciliation of GAAP to Non-GAAP Metrics (Unaudited, in thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| Adjusted EBITDA: | 2024 | 2023 | ||||||
| Net loss | $ | (6,499 | ) | $ | (5,239 | ) | ||
| Add: Other income (expense) , net | (177 | ) | (112 | ) | ||||
| Add: Depreciation | 439 | 279 | ||||||
| Add: Share-based compensation | 885 | 533 | ||||||
| Add: Income tax expense (benefit) | (80 | ) | 33 | |||||
| Total adjustments | 1,421 | 957 | ||||||
| Adjusted EBITDA | $ | (5,078 | ) | $ | (4,282 | ) | ||
| Adjusted Operating Expenses: | ||||||||
| Total operating expenses | $ | 12,743 | $ | 9,480 | ||||
| Less: Share-based compensation | 844 | 507 | ||||||
| Adjusted operating expenses | $ | 11,899 | $ | 8,973 | ||||
FAQ
What was Augmedix's revenue growth for Q1 2024?
How much did Augmedix's gross profit increase in Q1 2024?
What is Augmedix's net revenue retention rate for Q1 2024?
What is Augmedix's revenue guidance for 2024?
Why did Augmedix adjust its revenue outlook for 2024?
What was Augmedix's net loss for Q1 2024?
How much did Augmedix's operating expenses increase in Q1 2024?
